Skip Nav Destination
1-10 of 10
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
PTPN1 Deficiency Accelerates the Progression to Myelofibrosis in JAK2V617F-Driven Myeloproliferative Neoplasm
Blood (2022) 140 (Supplement 1): 3855.
Blood (2021) 138 (Supplement 1): 1465.
IL-1 Signaling Promotes Clonal Expansion and Progression of Bone Marrow Fibrosis in JAK2V617F-Induced Myeloproliferative Neoplasm
Blood (2021) 138 (Supplement 1): 2540.
Blood (2020) 136 (Supplement 1): 9.
The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models
Blood (2019) 134 (Supplement_1): 4200.
Blood (2019) 134 (Supplement_1): 1195.
The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models
Dipmoy Nath, PhD, Avik Dutta, MSc, Yue Yang, BS, Clifford Whatcott, PhD, Steven L. Warner, PhD, Golam Mohi, PhD
Blood (2018) 132 (Supplement 1): 54.
The NF-KB Inhibitor DMAPT in Combination with Ruxolitinib Displays Efficacy in Jak2V617F Knock-in Mouse Model of Myeloproliferative Neoplasms
Blood (2018) 132 (Supplement 1): 1783.
Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm
Blood (2016) 127 (26): 3410–3423.
Includes: Supplemental data
Loss of EZH2 Inhibits Erythropoiesis and Accelerates the Development of Myelofibrosis in Jak2V617F Knock-in Mice
Blood (2014) 124 (21): 159.